Filing Flows › OptimizeRx (OPRX) › Q2 2026 › vs Q1 2026
OptimizeRx (OPRX) Q2 2026 vs Q1 2026 (quarter over quarter)
OptimizeRx's revenue rose $660K (+3%) from $19.8M in Q1 2026 to $20.5M in Q2 2026.
OptimizeRx, Q2 2026: revenue $20.5M (-30% year over year), operating margin -0.4%, net loss $703K, operating cash flow $8.6M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 41.8% | -2.5% | +44.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $20.5M | $19.8M | $660K | +3% |
| Income tax benefit | $393K | $149K | $244K | +164% |
| Net loss | $703K | $495K | $208K | +42% |
| Costs & expenses | $21.6M | $20.5M | $1.1M | +5% |
| Operating costs | $20.6M | $19.4M | $1.1M | +6% |
| Interest & other, net | $1.0M | $1.0M | −$32K | -3% |
| Cost of revenue | $4.8M | $4.9M | −$96K | -2% |
| Research & development | $3.3M | $3.4M | −$128K | -4% |
| Sales & marketing | $5.5M | $4.7M | $799K | +17% |
| General & admin | $3.7M | $3.5M | $189K | +5% |
| Other operating costs | $3.3M | $2.9M | $380K | +13% |
| Operating cash sources | $9.3M | $28K | $9.3M | 333× |
| Depreciation & amortization | $1.1M | $1.1M | $0 | 0% |
| Share-based compensation | $2.2M | $1.8M | $380K | +21% |
| Working capital & other | $6.0M | −$2.9M | $8.9M | — |
| Net loss absorbed | $703K | $495K | $208K | +42% |
| Operating cash flow | $8.6M | −$467K | $9.1M | — |
| Free cash flow (OCF − capex) | $8.6M | −$488K | $9.1M | — |
| Capital expenditures | $35K | $21K | $14K | +67% |
Questions
How much did OptimizeRx's revenue grow quarter over quarter in Q2 2026?
OptimizeRx's revenue rose $660K (+3%) from $19.8M in Q1 2026 to $20.5M in Q2 2026.